TY - JOUR
T1 - Japanese guidelines for the management of pemphigoid (including epidermolysis bullosa acquisita)
AU - Committee for Guidelines for the Management of Pemphigoid Diseases (Including Epidermolysis Bullosa Acquisita)
AU - Ujiie, Hideyuki
AU - Iwata, Hiroaki
AU - Yamagami, Jun
AU - Nakama, Takekuni
AU - Aoyama, Yumi
AU - Ikeda, Shigaku
AU - Ishii, Norito
AU - Iwatsuki, Keiji
AU - Kurosawa, Michiko
AU - Sawamura, Daisuke
AU - Tanikawa, Akiko
AU - Tsuruta, Daisuke
AU - Nishie, Wataru
AU - Fujimoto, Wataru
AU - Amagai, Masayuki
AU - Shimizu, Hiroshi
N1 - Funding Information:
The creation of these guidelines was supported by a MHLW Health and Labor Sciences Research Grant for the Research on Rare Intractable Dermatological Disorders as part of the MHLW Research Project on Overcoming Intractable Diseases and by the Japanese Dermatological Association. No support was received from specific bodies or pharmaceutical companies. No conflicts of interest should be declared by each committee member regarding the formulation of this guideline.
Publisher Copyright:
© 2019 Japanese Dermatological Association
PY - 2019
Y1 - 2019
N2 - The pemphigoid group is a category of autoimmune subepidermal blistering diseases in which autoantibodies deposit linearly at the epidermal basement membrane zone (BMZ). The main subtypes of pemphigoid mediated by immunoglobulin G autoantibodies are bullous pemphigoid (BP), mucous membrane pemphigoid (MMP) and epidermolysis bullosa acquisita (EBA). To establish the first guidelines approved by the Japanese Dermatological Association for the management of pemphigoid diseases, the Committee for Guidelines for the Management of Pemphigoid Diseases (Including EBA) was founded as part of the Study Group for Rare Intractable Skin Diseases under the Ministry of Health, Labor and Welfare Research Project on Overcoming Intractable Diseases. These guidelines aim to provide current information for the management of BP, MMP and EBA in Japan. Based on evidence, the guidelines summarize the clinical and immunological manifestations, pathophysiologies, diagnostic criteria, disease severity determination criteria, treatment algorithms and treatment recommendations. Because of the rarity of these diseases, there are few clinical studies with a high degree of evidence, so several parts of these guidelines were established based on the opinions of the Committee. To further optimize these guidelines, periodic revision in line with the new evidence is necessary.
AB - The pemphigoid group is a category of autoimmune subepidermal blistering diseases in which autoantibodies deposit linearly at the epidermal basement membrane zone (BMZ). The main subtypes of pemphigoid mediated by immunoglobulin G autoantibodies are bullous pemphigoid (BP), mucous membrane pemphigoid (MMP) and epidermolysis bullosa acquisita (EBA). To establish the first guidelines approved by the Japanese Dermatological Association for the management of pemphigoid diseases, the Committee for Guidelines for the Management of Pemphigoid Diseases (Including EBA) was founded as part of the Study Group for Rare Intractable Skin Diseases under the Ministry of Health, Labor and Welfare Research Project on Overcoming Intractable Diseases. These guidelines aim to provide current information for the management of BP, MMP and EBA in Japan. Based on evidence, the guidelines summarize the clinical and immunological manifestations, pathophysiologies, diagnostic criteria, disease severity determination criteria, treatment algorithms and treatment recommendations. Because of the rarity of these diseases, there are few clinical studies with a high degree of evidence, so several parts of these guidelines were established based on the opinions of the Committee. To further optimize these guidelines, periodic revision in line with the new evidence is necessary.
KW - autoimmune blistering diseases
KW - bullous pemphigoid
KW - epidermolysis bullosa acquisita
KW - mucous membrane pemphigoid
KW - treatment algorithm
UR - http://www.scopus.com/inward/record.url?scp=85075963406&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85075963406&partnerID=8YFLogxK
U2 - 10.1111/1346-8138.15111
DO - 10.1111/1346-8138.15111
M3 - Article
C2 - 31646663
AN - SCOPUS:85075963406
SN - 0385-2407
JO - Journal of Dermatology
JF - Journal of Dermatology
ER -